Dynamics of cognitive functions and vegetative status in patients with arterial hypertension of working age on the background of Mexidol treatment

E.V. Bolotova

Kuban State Medical University

ORCID: 0000-0001-6257-354X

T.Yu. Zabolotskaya

Kuban State Medical University;
Scientific Research Institute — Ochapovsky Regional Clinic Hospital

ORCID: 0000-0003-3222-3076

T.I. Frolova

Kuban State Medical University;
Scientific Research Institute — Ochapovsky Regional Clinic Hospital

ORCID: 0009-0005-7711-3817

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12): 100–105

Dynamics of cognitive functions and vegetative status in patients with arterial hypertension of working age on the background of Mexidol treatment

Authors:

E.V. Bolotova, T.Yu. Zabolotskaya, T.I. Frolova

More about the authors

DOI: 10.17116/jnevro2025125121100

Read: 2268 times

Open to cite this article

Bolotova EV, Zabolotskaya TYu, Frolova TI. Dynamics of cognitive functions and vegetative status in patients with arterial hypertension of working age on the background of Mexidol treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(12):100‑105. (In Russ., In Engl.).
https://doi.org/10.17116/jnevro2025125121100

Close metadata

OBJECTIVE

To study the dynamics of cognitive functions and vegetative status on sequential therapy with Mexidol in patients with arterial hypertension of working age.

MATERIAL AND METHODS

A prospective, observational, randomized trial involving 65 patients with hypertension (33 women and 32 men, mean age 42.5±5.1 years). The patients divided into 2 groups, comparable in age and gender. In addition to antihypertensive therapy, patients in the main group (35 people) prescribed sequential therapy with Mexidol and Mexidol FORTE 250. Patients tested on scales reflecting vegetative, psycho-emotional and cognitive status (A.M. Wein scale, HADS scale, EQ-5D scale, A.R. Luria test, Schulte tables) before and 75 days after sequential Mexidol therapy.

RESULTS

On the background of Mexidol therapy, patients with hypertension showed positive dynamics in the form of an improvement in vegetative status on the A.M. Wein scale (21.3±7, vs 9.8±5.2, p=0.0438), a decrease in anxiety and depression on the HADS scale (7.3±2.7 vs 5.8±1.8, p=0.0197 and 8.3±0.7 vs 6.4±0.6, p=0.045, respectively), increased self-assessment of health status on the EQ-5D scale (52.3±8.5 vs 79±11.3, p=0.0362), decreased execution time in the Schulte test (243.6±47.1 vs 156.1±34.2, p=0.00001), increased word reproduction rates in the A.R. Luria test (6.1±0.98 vs 7.5±0.65, p=0.00001 and 5.5±0.81 vs 7.6±0.60, p=0.0001).

CONCLUSION

According to the results of the presented study conducted in patients with hypertension of working age, consistent therapy with Mexidol significantly improved the emotional background of patients, self-assessment of health status, vegetative status, cognitive function compared with patients with hypertension who received only hypotensive therapy.

Keywords:

arterial hypertension

working age

mexidol

autonomic dysfunction

cognitive impairment

Authors:

E.V. Bolotova

Kuban State Medical University

ORCID: 0000-0001-6257-354X

T.Yu. Zabolotskaya

Kuban State Medical University;
Scientific Research Institute — Ochapovsky Regional Clinic Hospital

ORCID: 0000-0003-3222-3076

T.I. Frolova

Kuban State Medical University;
Scientific Research Institute — Ochapovsky Regional Clinic Hospital

ORCID: 0009-0005-7711-3817

Received:

14.10.2025

Accepted:

20.10.2025

List of references:

Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.). https://doi.org/10.15829/1728-8800-2014-4-4-14
Shi Y, Thrippleton MJ, Makin SD, et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016;36(10):1653–67. https://doi.org/10.1177/0271678X16662891
Gottesman RF, Albert MS, Alonso A, et al. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol. 2017;74(10):1246-1254. https://doi.org/10.1001/jamaneurol.2017.1658
Martynov MU, Zhuravleva MV, Vasyukova NS, et al. Oxidative stress in the pathogenesis of stroke and its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(1):16-27. (In Russ., In Engl.). https://doi.org/10.17116/jnevro202312301116
Stijntjes M, Aartsen MJ, Taekema DG, et al. Temporal Relationship Between Cognitive and Physical Performance in Middle-Aged to Oldest Old People. J Gerontol. 2017;72(5):662-668. https://doi.org/10.1093/gerona/glw133
Dashieva EB, Petrova MM, Kaskaeva DS. Arterial hypertension in young people: the basic factors of its development risks. Siberian Medical Review. 2020;(4):12-19. (In Russ.). https://doi.org/10.20333/2500136-2020-4-12-19
Nalbat AV, Yakupov EZ, Khuzyasheva EI. Autonomic disorders associated with different forms of cerebrovascular pathology. Neurology Bulletin. 2012;XLIV(3):100-108. (In Russ.).
Gusev EI, Bogolepova AN. Depressive disorders in patients with cerebrovascular disease. 2nd ed. Moscow: MEDpress-inform. 2017: 208 pp. (In Russ.).
Fedin AI. Arterial hypertension and cognitive impairment. Neurologist’s view. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11):1-7. (In Russ.). https://doi.org/10.17116/jnevro20231231117
Ostroumova OD, Parfenov VA, Ostroumova TM, et al. Konsensus ekspertov. Vliyanie antigipertenzivnoi terapii na kognitivnye funktsii. Sistemnye gipertenzii. 2021;18(1):5-12. (In Russ.). https://doi.org/10.26442/2075082X.2021.1.200575
Zaharov VV, Tkacheva ON, Mkhitaryan EA, et al. Efficacy of Mexidol in patients with chronic brain ischemia and cognitive impairment of different age groups (results of sub-analysis of the international multicenter, randomized, double-blind, placebo-controlled study of sequential therapy in patients with chronic brain ischemia MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11-2):73-80. (In Russ.). https://doi.org/10.17116/jnevro202212211273
Kochetkov AI, Shatalova NA, Klepikova MV, et al. More on the neuroprotectory therapy evidential base: Focus at ethylmethyl hydroxypyridine succinate. Therapy. 2023;9(8):162-172. (In Russ.). https://doi.org/10.18565/therapy.2023.8.162-172.
Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;27(10):72-83. (In Russ.). https://doi.org/10.17116/profmed20242710172
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Antipenko EA, Shulyndin AV, Belyakov KM. Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):42-51. (In Russ.). https://doi.org/10.17116/jnevro202412403142